Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 266

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 11
Chunk 266
---
 days of days of March 12, 2025.

    (6)
    Consists
    of (i) 202,859 shares of common stock, (ii) 127,485 shares of common stock issuable upon exercise of warrants, and (ii) 705,292 shares
    of common stock issuable upon exercise of outstanding options, of which 16,667 will vest within 60 days of days of March 12, 2025.

    (7)
    Consists
    of 83,750 shares of common stock issuable upon exercise of outstanding options, of which 13,750 will vest within 60 days of March
    12, 2025.

    (8)
    Consists
    of (i) 150 shares of common stock and (ii) 325,750 shares of common stock issuable upon exercise of outstanding options, of which
    9,583 will vest within 60 days of March 12, 2025.

    (9)
    Consists
    of 41,281 shares of common stock issuable upon exercise of outstanding options.

    (10)
    Consists of
    (i) 670 shares of common stock and (ii) 41,000 shares of common stock issuable upon exercise of outstanding options.

    (11)
    Consists of
    41,000 shares of common stock issuable upon exercise of outstanding options.

    (12)
    Consists of
    154,000 shares of common stock issuable upon exercise of outstanding options.

    (13)
    Consists of
    46,250 shares of common stock issuable upon exercise of outstanding options.

    (14)
    Consists of
    20,000 shares of common stock issuable upon exercise of outstanding options.

    (15)
    Consists of
    (i) 1,572,035 shares of common stock, (ii) 127,485 shares of common stock issuable upon exercise of warrants, and (ii) 1,957,242
    shares of common stock issuable upon exercise of outstanding options, of which 53,875 will vest within 60 days of days of March 12,
    2025.

92

Item
13. Certain Relationships and Related Transactions, and Director Independence.

Policies
and Procedures for Related Person Transactions

In
accordance with our audit committee charter, the Audit Committee is required to approve related